DexCom, Inc. (DXCM) Expected to Post Quarterly Sales of $246.45 Million

Equities analysts expect DexCom, Inc. (NASDAQ:DXCM) to report sales of $246.45 million for the current quarter, according to Zacks. Ten analysts have made estimates for DexCom’s earnings, with the highest sales estimate coming in at $279.20 million and the lowest estimate coming in at $232.80 million. DexCom reported sales of $184.40 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 33.6%. The firm is expected to issue its next earnings report after the market closes on Wednesday, May 1st.

According to Zacks, analysts expect that DexCom will report full year sales of $1.23 billion for the current fiscal year, with estimates ranging from $1.21 billion to $1.25 billion. For the next year, analysts expect that the firm will post sales of $1.44 billion, with estimates ranging from $1.32 billion to $1.54 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for DexCom.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 21st. The medical device company reported $0.54 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.38. DexCom had a positive return on equity of 4.98% and a negative net margin of 12.32%. The company had revenue of $338.00 million for the quarter, compared to analyst estimates of $331.60 million. During the same quarter last year, the firm earned $0.10 EPS. DexCom’s revenue for the quarter was up 52.9% compared to the same quarter last year.

DXCM has been the topic of several recent research reports. Morgan Stanley lifted their price objective on DexCom from $135.00 to $160.00 and gave the stock an “equal weight” rating in a report on Monday, February 25th. Piper Jaffray Companies boosted their price target on DexCom to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, January 9th. UBS Group boosted their price target on DexCom from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, January 8th. Cowen boosted their price target on DexCom from $150.00 to $175.00 and gave the company an “outperform” rating in a research note on Friday, February 22nd. Finally, Canaccord Genuity boosted their price target on DexCom from $140.00 to $160.00 and gave the company a “buy” rating in a research note on Friday, February 22nd. Six equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $149.53.

In other DexCom news, EVP Steven Robert Pacelli sold 3,114 shares of DexCom stock in a transaction on Wednesday, January 23rd. The stock was sold at an average price of $149.74, for a total value of $466,290.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 6,000 shares of DexCom stock in a transaction on Monday, February 11th. The shares were sold at an average price of $148.90, for a total value of $893,400.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 96,048 shares of company stock valued at $13,514,383. Corporate insiders own 1.80% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of DXCM. Laurel Wealth Advisors LLC bought a new position in DexCom in the 4th quarter valued at $26,000. Harel Insurance Investments & Financial Services Ltd. bought a new position in DexCom in the 4th quarter valued at $33,000. Canton Hathaway LLC bought a new position in DexCom in the 1st quarter valued at $41,000. First Hawaiian Bank raised its position in DexCom by 75.6% in the 4th quarter. First Hawaiian Bank now owns 395 shares of the medical device company’s stock valued at $47,000 after purchasing an additional 170 shares during the last quarter. Finally, Bremer Trust National Association bought a new position in DexCom in the 4th quarter valued at $49,000. Hedge funds and other institutional investors own 97.96% of the company’s stock.

Shares of NASDAQ:DXCM opened at $114.29 on Friday. DexCom has a 1-year low of $72.04 and a 1-year high of $156.16. The company has a market cap of $10.29 billion, a PE ratio of 394.10 and a beta of 0.75. The company has a current ratio of 7.64, a quick ratio of 7.32 and a debt-to-equity ratio of 1.52.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Read More: Bond

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.